Can CereVasc’s $85m raise move hydrocephalus treatment beyond traditional shunt surgery?
CereVasc’s $85m raise backs eShunt, a minimally invasive hydrocephalus device. The STRIDE trial now carries the real test.
Can CereVasc’s eShunt system change the future of idiopathic intracranial hypertension treatment?
CereVasc’s eShunt system shows three-year outcomes in idiopathic intracranial hypertension. Discover what this means for future brain pressure treatments.
Could CereVasc’s eShunt replace VP shunts in post-aneurysmal hydrocephalus treatment?
CereVasc completes ETCHES trial enrollment for its eShunt device in post-SAH hydrocephalus. Learn what this means for future neurosurgical care.